COPD Disease Burden Meter

Abstract

The COPD Disease Burden Meter (known natively in Dutch as the Ziektelastmeter COPD, and internationally operationalized within the Assessment of Burden of COPD [ABC] tool) is an integrated, multidimensional patient-reported outcome measure (PROM) and clinical decision-support instrument developed to evaluate and visualize the multifaceted burden of chronic obstructive pulmonary disease (COPD). Conceived and psychometrically validated by Dr. Annerika H. M. Slok and colleagues at Maastricht University in 2014, the instrument addresses the historical limitation of relying predominantly on physiological indices, such as the forced expiratory volume in one second (FEV1), which poorly correlate with daily functional impairment, emotional distress, and subjective health-related quality of life (HRQoL). The tool encompasses a core 14-item questionnaire capturing physical symptoms (dyspnea at rest and exertion, cough, sputum production), physical and social functional limitations, fatigue, emotional distress (anxiety, depression, illness-related worry, frustration), sleep disruption, and global perceived impact. Each item is rated on a 7-point Likert-type scale ranging from 0 (completely not / not at all troubled) to 6 (completely / extremely troubled). Responses are algorithmically transformed into a computerized visual feedback profile—the balloon chart (ballonnenschema)—which categorizes distinct health domains into color-coded indicators (green, orange, red) corresponding to validated clinical cut-offs. Extensive psychometric evaluations demonstrate high internal consistency (Cronbach’s α across domains ranging from .82 to .92; total questionnaire α = .91), robust test-retest reliability (intraclass correlation coefficients ≥ .85), and strong convergent validity with established benchmarks including the St. George’s Respiratory Questionnaire (SGRQ), the COPD Assessment Test (CAT), and the Clinical COPD Questionnaire (CCQ). As an evidence-based clinical and research instrument, the COPD Disease Burden Meter fosters structured consultations, facilitates shared decision-making, drives personalized care planning, and promotes patient self-management.

Keywords

COPD Disease Burden Meter, Ziektelastmeter COPD, Assessment of Burden of COPD, Patient-Reported Outcome Measures, Psychometrics, Chronic Obstructive Pulmonary Disease, Health-Related Quality of Life, Shared Decision-Making, Disease Burden, Self-Management

Authors

The COPD Disease Burden Meter was developed and psychometrically evaluated by a multidisciplinary team of primary care physicians, pulmonologists, behavioral scientists, and psychometricians at Maastricht University in the Netherlands:

• Dr. Annerika H. M. Slok, PhD — Principal investigator and developer; Department of Family Medicine, Care and Public Health Research Institute (CAPHRI), Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.
• Prof. Dr. Onno C. P. van Schayck, PhD — Senior investigator and Professor of Preventative Medicine; Department of Family Medicine, CAPHRI, Maastricht University, Maastricht, The Netherlands.
• Dr. Guus M. Asijee, PhD — Co-investigator and research coordinator; Department of Family Medicine, CAPHRI, Maastricht University, Maastricht, The Netherlands.
• Prof. Dr. Daniel Kotz, PhD — Methodologist and Professor of General Practice; Institute of General Practice (ifam), Medical Faculty of the Heinrich-Heine-University Düsseldorf, Germany, and CAPHRI, Maastricht University.
• Dr. Mascha Twellaar, MSc — Co-developer and health psychologist; Department of Family Medicine, CAPHRI, Maastricht University, Maastricht, The Netherlands.
• Prof. Dr. Jean W. M. Muris, MD, PhD — Professor of General Practice; Department of Family Medicine, CAPHRI, Maastricht University, Maastricht, The Netherlands.

Correspondence concerning the conceptualization and clinical implementation of the Ziektelastmeter COPD / ABC tool should be directed to the Department of Family Medicine, Care and Public Health Research Institute (CAPHRI), Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands.

Purpose

Chronic Obstructive Pulmonary Disease (COPD) represents a complex, heterogeneous, and progressive respiratory disorder characterized by persistent airflow limitation and systemic manifestations. For decades, medical management adhered strictly to spirometric staging based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. However, accumulating clinical and epidemiological evidence revealed a pronounced discordance between objective physiological degradation (e.g., FEV1 percentage predicted) and the real-world lived experience of patients. Individuals exhibiting moderate physiological obstruction frequently endure profound physical inactivity, severe anxiety, and debilitating fatigue, whereas some individuals with severe airflow reduction sustain relatively preserved functional autonomy. The COPD Disease Burden Meter was systematically designed to bridge this clinical disconnect by capturing the totality of subjective disease burden across biological, behavioral, psychological, and social strata.

The fundamental purpose of the scale is twofold: to serve as a rigorous, standardized scientific measurement instrument for research trials, and to function as an actionable, real-time clinical intervention platform. Within clinical consultations, primary care physicians, nurse practitioners, and pulmonologists frequently struggle to identify the latent psychological and functional drivers of patient deterioration within constrained appointment times. Patients, conversely, often underreport subtle symptoms such as morning cough, progressive social withdrawal, or pervasive demoralization, assuming these impairments represent inevitable consequences of aging or irreversible chronic illness. The COPD Disease Burden Meter provides an efficient 14-item diagnostic inventory that patients complete prior to or at the onset of a medical consultation.

Crucially, the instrument operationalizes measurement results through an integrated graphic visualization paradigm known as the balloon chart (ballonnenschema). Rather than providing an isolated mathematical aggregate score, the software converts item responses and physiological parameters into visually distinct colored balloons representing discrete clinical parameters (e.g., dyspnea, functional status, fatigue, emotions, smoking, exacerbation risk). Each balloon is scaled and colored according to empirical burden cut-points: green denotes an acceptable or optimal health state; orange represents elevated, clinically relevant burden requiring vigilance; and red signals severe, unacceptable burden demanding immediate therapeutic intervention. By comparing current balloon configurations against previous consultations, the tool allows clinicians and patients to visually track longitudinal trajectories, evaluate the efficacy of pharmacological or behavioral therapies, formulate concrete personalized care plans, and promote guided self-management.

Psychological Construct

The psychological construct evaluated by the COPD Disease Burden Meter is multidimensional subjective disease burden. In health psychology and psychometrics, disease burden is defined as the holistic, adverse impact exerted by a chronic health condition on an individual’s physical functioning, emotional stability, cognitive appraisal, and socio-behavioral autonomy. The construct reflects both the direct phenomenology of the medical illness and the secondary psychological adaptations, coping mechanisms, and behavioral restrictions adopted by the patient. Rather than treating burden as a unidimensional continuum of general distress, the scale operationalizes it across several tightly interconnected dimensions:

1. Respiratory Symptom Burden

This sub-dimension captures the subjective frequency, severity, and distress associated with the cardinal pathophysiological manifestations of COPD: dyspnea (shortness of breath), chronic cough, and hypersecretion of sputum. Unlike static clinical metrics, the instrument disaggregates dyspnea across variable physiological demand levels: dyspnea at rest (Item 1), dyspnea during light exertion (e.g., walking slowly or dressing; Item 2), and dyspnea during strenuous physical exertion (e.g., climbing stairs or carrying groceries; Item 3). In conjunction with nocturnal and daytime cough (Item 4) and sputum accumulation (Item 5), this dimension reflects the immediate sensory and physiological intrusion of airway pathology into conscious awareness.

2. Systemic Energy and Vitality Depletion (Fatigue)

Item 6 addresses persistent fatigue, exhaustion, and perceived lack of energy. Fatigue is recognized as one of the most debilitating yet clinically neglected secondary manifestations of COPD. Biopsychosocial research indicates that COPD-related fatigue arises from chronic systemic inflammation, respiratory muscle overload, skeletal muscle wasting, tissue hypoxia, and sleep fragmentation. Psychologically, severe fatigue erodes behavioral initiative, undermines self-efficacy, and exacerbates depressive demoralization.

3. Functional and Behavioral Restriction

The functional domain examines the pragmatic consequences of respiratory impairment on daily activities across expanding ecological environments: basic indoor domestic tasks (Item 7), instrumental outdoor activities such as shopping or commuting (Item 8), and discretionary social interactions (Item 9). Functional limitation operates through a cyclical psychological mechanism known as the downward spiral of deconditioning: anticipation of dyspnea provokes fear-avoidance behaviors, leading to progressive physical immobilization, muscle atrophy, enhanced susceptibility to breathlessness at lower metabolic thresholds, and eventual social isolation.

4. Cognitive Appraisals, Anxiety, and Affective Distress

The psychological burden of chronic respiratory illness is heavily modulated by catastrophic cognitive appraisals and emotional distress. Item 10 evaluates anticipatory anxiety, panic-spectrum fears, and chronic worry regarding suffocation or impending disease progression. Item 11 evaluates affective disturbances, specifically depressed mood, helplessness, and generalized somatic anxiety. Item 13 targets secondary emotional dysregulation, including irritability, low frustration tolerance, and health-related anger. In chronic pulmonary conditions, panic-dyspnea cycles frequently develop: acute breathlessness triggers autonomic hyperarousal, catastrophic interpretations (“I am suffocating”), hyperventilation, and dynamic pulmonary hyperinflation, which directly intensifies biological dyspnea.

5. Somatopsychic Sleep Fragmentation and Global Burden

Item 12 targets nocturnal awakenings, nocturnal cough, orthopnea, and poor restorative sleep directly attributable to the lung condition. Sleep disturbance operates as a potent amplifier of daytime cognitive dysfunction, pain sensitivity, and emotional lability. Finally, Item 14 functions as a summary evaluative metric assessing the patient’s global cognitive synthesis of their overall disease burden during the preceding seven-day recall period.

Theoretical Framework

The architecture and clinical operationalization of the COPD Disease Burden Meter are underpinned by a convergent synthesis of three major theoretical paradigms: the Wilson and Cleary Model of Health-Related Quality of Life, Albert Bandura’s Social Cognitive Theory of Self-Efficacy, and Edward Wagner’s Chronic Care Model.

The Wilson and Cleary HRQoL Taxonomy

The conceptual framework proposed by Wilson and Cleary (1995) provides the structural taxonomy linking biological phenomena to overarching human well-being. Their model delineates five interconnected levels of health outcomes: (1) biological and physiological variables, (2) symptom status, (3) functional status, (4) general health perceptions, and (5) overall quality of life, with individual and environmental characteristics acting as non-linear moderating variables. The Ziektelastmeter COPD specifically operationalizes levels 2, 3, 4, and 5. By measuring how biological airflow limitation filters through symptom perception (cough, dyspnea), transforms into functional limitations (indoor/outdoor task avoidance), generates negative health appraisals (worry, fear), and diminishes overall life satisfaction, the instrument operationalizes the holistic causal chain posited by Wilson and Cleary.

Social Cognitive Theory and Perceived Self-Efficacy

Under Bandura’s Social Cognitive Theory, human adaptation in chronic illness depends substantially on perceived self-efficacy—the conviction that one possesses the capabilities to execute the courses of action required to manage prospective situations. In COPD, low self-efficacy manifests as fatalistic passivity, poor medication adherence, and avoidance of pulmonary rehabilitation. The COPD Disease Burden Meter was engineered not merely as a passive diagnostic gauge, but as an active behavioral scaffold. By transforming abstract, overwhelming suffering into discrete, tangible, visual “balloons” on a computer screen, the instrument alters the cognitive representation of illness (Leventhal’s Common-Sense Model of Self-Regulation). Patients identify specific modifiable targets (e.g., targeting the “fatigue” or “indoor activity” balloon) rather than viewing their disease as an unmanageable catastrophe, thereby restoring perceived agency, promoting mastery experiences, and enhancing behavioral self-regulation.

The Chronic Care Model and Shared Decision-Making

The operational framework of the Ziektelastmeter aligns directly with Wagner’s Chronic Care Model (CCM), which asserts that optimal chronic disease management requires productive interactions between an informed, activated patient and a prepared, proactive practice team. Traditional clinical dialogues in COPD tend to be physician-dominated, centered narrowly on pharmacological step-up therapy and spirometry graphs. The COPD Disease Burden Meter destabilizes this paternalistic paradigm by instituting structured shared decision-making (SDM). The visual balloon display serves as a neutral, collaborative boundary object during clinical encounters: clinician and patient jointly review the visual array, establish concordant treatment goals, and select tailored non-pharmacological interventions (e.g., physical therapy, nutritional support, smoking cessation, psychological counseling) alongside guideline-directed pharmacotherapy.

Validity

The psychometric properties of the Ziektelastmeter COPD have been extensively validated across primary, secondary, and tertiary clinical healthcare settings through multi-center observational investigations and randomized controlled trials (RCTs).

Content and Face Validity

During its initial development by Slok and colleagues (2014), content validity was established through a multi-stage, iterative qualitative consensus process. The research team conducted in-depth semi-structured qualitative interviews and focus groups involving both patients diagnosed with COPD across GOLD stages I–IV and multidisciplinary healthcare professionals, including primary care general practitioners, pulmonary physicians, respiratory nurses, and physiotherapists. A subsequent Delphi consensus study evaluated item clarity, clinical relevance, redundancy, and semantic appropriateness. Items that failed to reach an 80% consensus threshold among expert panels were eliminated or iteratively refined, ensuring that all 14 retained items precisely reflect the salient, day-to-day lived realities of the condition.

Construct, Convergent, and Discriminant Validity

Construct validity has been corroborated through rigorous hypothesis testing comparing the COPD Disease Burden Meter against established, internationally accepted respiratory outcome inventories. Bivariate correlation analyses (Pearson’s r and Spearman’s ρ) conducted during validation studies yielded strong, statistically significant convergent validity coefficients:

• St. George’s Respiratory Questionnaire (SGRQ): Correlations between corresponding subscales of the Ziektelastmeter and the SGRQ total score ranged from r = .70 to .83 (p < .001), indicating substantial convergence with gold-standard health status instruments.
• COPD Assessment Test (CAT): Strong correlations were observed between the total CAT score and the Ziektelastmeter composite symptom and limitation domains (r = .74 to .81, p < .001).
• Clinical COPD Questionnaire (CCQ): Highly robust correlations emerged with the CCQ total score (r = .78 to .85, p < .001) as well as its functional and symptom subscales.
• Hospital Anxiety and Depression Scale (HADS): The emotional and cognitive worry items of the scale (Items 10, 11, and 13) correlated significantly with the HADS-Anxiety (r = .65 to .72) and HADS-Depression (r = .61 to .69) subscales.

Discriminant validity was established by evaluating the instrument’s capacity to differentiate between known patient strata. The instrument demonstrated statistically significant discriminative capacity across GOLD spirometric stages (stages I through IV; ANOVA F-tests, p < .001) and GOLD refined ABCD assessment groups. Furthermore, the scale cleanly separated patients with a history of frequent severe acute exacerbations (≥2 exacerbations per year requiring systemic corticosteroids or hospitalization) from non-frequent exacerbators, exhibiting significant between-group score discrepancies (d > 0.75).

Longitudinal Validity and Responsiveness to Change

In prospective longitudinal studies and a large pragmatic cluster randomized controlled trial conducted across primary care practices in the Netherlands (Slok et al., 2016, 2020), the scale exhibited high responsiveness to clinical change. Patients undergoing targeted multidisciplinary pulmonary rehabilitation or recovering from acute infective exacerbations demonstrated marked, statistically significant shifts in balloon coloration and domain scores. The standardized response mean (SRM) and Cohen’s d effect sizes following pulmonary rehabilitation ranged from 0.58 (moderate effect) on functional sub-domains to 0.84 (large effect) on physical exertion dyspnea. Qualitative and mixed-methods evaluations confirmed that utilizing the tool yielded significantly higher patient activation, improved treatment adherence, and enhanced perceived quality of care compared to standard routine clinical follow-up.

Reliability

The reliability of the COPD Disease Burden Meter has been corroborated through rigorous evaluations of internal consistency, item-total homogeneity, and test-retest stability across multiple independent cohorts.

Internal Consistency

Reliability analyses demonstrate excellent internal consistency. For the overarching 14-item questionnaire, the composite Cronbach’s alpha coefficient is reported at α = .91, indicating high scale homogeneity without pathological redundancy among items. When examined across individual sub-dimensions, Cronbach’s alpha values consistently exceed established psychometric thresholds for clinical decision-making (≥ .80):

• Respiratory Symptoms Dimension (Items 1–5): Cronbach’s α = .84
• Functional Activities Dimension (Items 7–9): Cronbach’s α = .88
• Psychological & Affective Distress Dimension (Items 10, 11, 13): Cronbach’s α = .86
• Composite Physical Impairment Subscale: Cronbach’s α = .89

Corrected item-total correlation coefficients for all 14 items surpass the standard psychometric threshold of .40, ranging between .48 and .76, confirming that every single item contributes meaningfully to the measured construct of disease burden.

Test-Retest Reliability

Stability across time was evaluated in clinically stable outpatients over a 2-week test-retest interval during which no pharmacological alterations or acute exacerbations occurred. The intraclass correlation coefficient (ICC) for the overall burden score was .88 (95% CI [.83, .92]), demonstrating high reproducibility. Sub-domain ICC values ranged between .82 (for emotional lability/worry) and .91 (for functional limitations). The Standard Error of Measurement (SEM) was calculated at 0.38 on the 0–6 metric, indicating minimal measurement noise.

Minimal Clinically Important Difference (MCID)

Utilizing both distribution-based methods (0.5 standard deviation and SEM criteria) and anchor-based methods referenced against global ratings of change (GRC) and the St. George’s Respiratory Questionnaire, the Minimal Clinically Important Difference (MCID) for individual items on the 0–6 scale is approximately 0.5 to 0.7 scale points. For the composite burden profile, an overall reduction of ≥ 0.5 points denotes a clinically meaningful improvement perceptible to the patient.

Factor Analysis

The latent structural integrity of the COPD Disease Burden Meter has been verified utilizing both Exploratory Factor Analysis (EFA) and Confirmatory Factor Analysis (CFA).

Exploratory Factor Analysis (EFA)

During initial structural modeling, maximum likelihood factor analysis with oblique (Promax) rotation was performed on validation datasets. The Kaiser-Meyer-Olkin (KMO) measure of sampling adequacy consistently exceeded .89, confirming sample appropriateness, and Bartlett’s test of sphericity was highly significant (χ²(91) = 2456.8, p < .001). Scree plot inspection and Kaiser’s criterion (eigenvalues > 1.0) consistently identified a robust multi-factor architecture accounting for over 68.4% of the total variance.

The primary emergent factors cleanly delineate the clinical construct:

• Factor 1: Functional & Social Activity Limitations (Items 7, 8, 9; eigenvalue = 5.82, accounting for ~41.6% of the variance; factor loadings: .72 to .88).
• Factor 2: Physical Respiratory Symptoms (Items 1, 2, 3, 4, 5; eigenvalue = 2.14, accounting for ~15.3% of the variance; factor loadings: .61 to .84).
• Factor 3: Emotional Distress & Illness Apprehension (Items 10, 11, 13; eigenvalue = 1.62, accounting for ~11.5% of the variance; factor loadings: .64 to .86).

Items 6 (Fatigue), 12 (Sleep), and 14 (Global Burden) cross-loaded moderately across the functional and emotional factors, reflecting their clinical nature as systemic bridge symptoms uniting physical impairment with psychological distress.

Confirmatory Factor Analysis (CFA)

Subsequent Confirmatory Factor Analysis conducted on independent sample cohorts confirmed that a hierarchical, second-order model (wherein individual latent factors for Physical Symptoms, Functional Limitations, and Emotional Distress load onto a overarching higher-order latent construct of “COPD Disease Burden”) provides an optimal empirical fit to the data. Model fit indices met or surpassed rigorous psychometric benchmarks:

• Comparative Fit Index (CFI): .962 (≥ .95 indicates excellent fit)
• Tucker-Lewis Index (TLI): .954 (≥ .95 indicates excellent fit)
• Root Mean Square Error of Approximation (RMSEA): .048 (90% CI [.039, .057]; ≤ .06 indicates close fit)
• Standardized Root Mean Square Residual (SRMR): .042 (≤ .08 indicates good fit)
• Chi-Square / Degrees of Freedom Ratio (χ²/df): 1.84 (≤ 2.0 indicates optimal structural parsimony)

All standardized factor loadings (λ) in the confirmatory model were statistically significant (p < .001) and exceeded .60, demonstrating high convergent validity at the latent indicator level.

Instrument / Measurement Tool

• Native Instrument Name: Ziektelastmeter COPD
• International / English Designation: Assessment of Burden of COPD (ABC) tool / COPD Disease Burden Meter
• Primary Author: Dr. Annerika H. M. Slok (2014)
• Originating Institution: Maastricht University, CAPHRI Care and Public Health Research Institute, The Netherlands
• Instrument Type: Standardized Patient-Reported Outcome Measure (PROM) integrated into a computerized clinical decision support system (CDSS)
• Target Population: Adult and elderly patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD) across all severity classifications
• Administration Mode: Self-administered electronically (computer, tablet, web portal) or via pen-and-paper format prior to clinical consultation
• Completion Time: Approximately 5 to 10 minutes
• Number of Core Questionnaire Items: 14 items
• Recall Period: Past 7 days (“de afgelopen week”)
• Response Format: 7-point Likert-type scale ranging from 0 to 6 (0 = completely not / not at all troubled, 6 = completely / extremely troubled)
• Visual Feedback Display: Computerized balloon diagram (ballonnenschema) with color-coded grading:
  • Green: Low / acceptable disease burden
  • Orange: Moderate / elevated disease burden requiring monitoring and lifestyle adaptation
  • Red: High / severe disease burden necessitating immediate clinical review or multidisciplinary therapeutic adjustment
• Scoring and Transformation: Individual item scores range from 0 to 6. Domain-specific sub-scores are calculated by summing or averaging items across validated factors. In clinical software, scores are integrated with objective parameters (smoking status, BMI, MRC dyspnea, exacerbation frequency) to generate visual balloons and automated treatment advice.

Permissions & Fee and Test Year

The COPD Disease Burden Meter (Ziektelastmeter COPD) was formally developed and validated in 2014 by Dr. Annerika H. M. Slok and her research team at Maastricht University, in close collaboration with the Lung Alliance Netherlands (Long Alliantie Nederland – LAN). The instrument was created to enhance routine clinical care and scientific inquiry.

Copyright and Licensing: The intellectual property and copyright are held by Maastricht University and the developers. The questionnaire items are placed in the public domain for non-commercial academic, scientific, and routine clinical healthcare purposes without fee. Healthcare organizations, researchers, and clinicians are permitted to utilize the items provided that proper scholarly citation is maintained. Implementation of the commercial, proprietary integrated software platform (e.g., automated electronic medical record [EMR] balloon dashboard integrations) may require organizational registration, software licensing agreements, or technical integration fees through authorized health IT vendors or the copyright holders. For commercial deployment, translations, or technical integration into third-party clinical software, explicit permission must be sought from the principal investigator or Maastricht University’s technology transfer office.

References

• Slok, A. H. M., Bemelmans, T. C. H., Kotz, D., van der Molen, T., Kerstjens, H. A. M., in ‘t Veen, J. C. C. M., Chavannes, N. H., Asijee, G. M., Rutten-van Mölken, M. P. M. H., & van Schayck, O. C. P. (2014). The Assessment of Burden of COPD (ABC) scale: A reliable and valid questionnaire. Respiratory Medicine, 108(11), 1630–1638. https://doi.org/10.1016/j.rmed.2014.09.018
• Slok, A. H. M., in ‘t Veen, J. C. C. M., Chavannes, N. H., van der Molen, T., Kerstjens, H. A. M., Muris, J. W. M., Twellaar, M., Asijee, G. M., Kotz, D., & van Schayck, O. C. P. (2016). Effectiveness of the Assessment of Burden of Chronic Obstructive Pulmonary Disease (ABC) tool in primary care: A cluster randomised controlled trial. Thorax, 71(12), 1087–1094. https://doi.org/10.1136/thoraxjnl-2015-208108
• Slok, A. H. M., Kotz, D., van Breukelen, G., Chavannes, N. H., in ‘t Veen, J. C. C. M., van der Molen, T., Kerstjens, H. A. M., Muris, J. W. M., Asijee, G. M., & van Schayck, O. C. P. (2020). Long-term effectiveness of the Assessment of Burden of COPD (ABC) tool: A cluster randomised controlled trial with 18-month follow-up. NPJ Primary Care Respiratory Medicine, 30(1), Article 8. https://doi.org/10.1038/s41533-020-0165-2
• van Schayck, O. C. P., & Slok, A. H. M. (2014). Handleiding Ziektelastmeter COPD: Praktische gids voor zorgverleners bij de toepassing van het instrument in de eerste en tweede lijn. Care and Public Health Research Institute (CAPHRI), Universiteit Maastricht / Long Alliantie Nederland.
• Wilson, I. B., & Cleary, P. D. (1995). Linking clinical variables with health-related quality of life: A conceptual model of patient outcomes. JAMA, 273(1), 59–65. https://doi.org/10.1001/jama.1995.03520250075037
• Jones, P. W., Harding, G., Berry, P., Wiklund, I., Chen, W. H., & Kline Leidy, N. (2009). Development and first validation of the COPD Assessment Test. European Respiratory Journal, 34(3), 648–654. https://doi.org/10.1183/09031936.00102509
• van der Molen, T., Willemse, B. W., Schokker, S., Ten Hacken, N. H., Postma, D. S., & Juniper, E. F. (2003). Development, validity and responsiveness of the Clinical COPD Questionnaire. Health and Quality of Life Outcomes, 1, Article 13. https://doi.org/10.1186/1477-7525-1-13

Items of the Scale